Updates are available Correction dated 2023-11-13

Article History

Accepted: 5 October 2023

First Online: 20 October 2023

Change Date: 13 November 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10741-023-10365-8

Declarations

:

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

: The authors did not receive payment related to the development of this manuscript. FF has declared no conflict of interest related to this manuscript. JN reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Rovi, and Vifor Pharma (outside of the submitted work). MJCM has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for Astra Zeneca, Vifor Pharma, Novartis, Boehringer-Ingelheim, Bayer, Novonordisk. MCM has declared no conflict of interest related to this manuscript. MIE has declared no conflict of interest related to this manuscript. CFG-P and AT-S are full-time employees and minority shareholders of Eli Lilly and Company España. AMG is full employee of Boehringer Ingelheim España. JMFR has declared no conflict of interest related to this manuscript.

: Writing and editorial assistance was provided by Content Ed Net (Madrid, Spain), which was contracted and funded by Boehringer Ingelheim.